Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Sections
Personal tools
Log in
You are here: Home Protocols Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase I

Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase I

1002
Kinsinger, ChrisNational Cancer Institute

CPTAC Phase I 2006 - 2011, was developed to address the pre-analytical and analytical variability issues that are major barriers to the field of proteomics. These barriers were: (1) experimental design; (2) technological and technical aspects of protein identification; (3) variability related to biospecimens collection; (4) the processes of data acquisition, analysis, and reporting; (5) the lack of reproducible proteomic technologies; and (6) the lack of highly characterized and standardized reagents. See https://cptacdcc.georgetown.edu/cptac/study/list?scope=Phase+I for more information.


CPTAC Phase I 2006 - 2011, was developed to address the pre-analytical and analytical variability issues that are major barriers to the field of proteomics. These barriers were: (1) experimental design; (2) technological and technical aspects of protein identification; (3) variability related to biospecimens collection; (4) the processes of data acquisition, analysis, and reporting; (5) the lack of reproducible proteomic technologies; and (6) the lack of highly characterized and standardized reagents. See https://cptacdcc.georgetown.edu/cptac/study/list?scope=Phase+I for more information.

There are currently no biomarkers annotated for this protocol.